Key result
Venopulmonary-ECMO bridge to lung transplant is linked to ~45-point higher 3-year survival than VA-ECMO.
Why the study?
Venopulmonary ECMO has emerged as a promising bridge to lung transplantation in advanced respiratory failure, motivating a comparison of mid-term outcomes against venoarterial-ECMO and venovenous-ECMO.
Does percutaneous venopulmonary-ECMO improve mid-term survival and freedom from chronic lung allograft dysfunction compared to venoarterial-ECMO or venovenous-ECMO in patients with advanced respiratory failure bridged to lung transplantation?
Cohort (n=99)
Does percutaneous venopulmonary-ECMO improve mid-term survival and freedom from chronic lung allograft dysfunction compared to venoarterial-ECMO or venovenous-ECMO in patients with advanced respiratory failure bridged to lung transplantation?
Percutaneous venopulmonary-ECMO is an effective bridge to lung transplantation that provides comparable bridging outcomes to venovenous-ECMO and superior mid-term survival and CLAD-free survival compared to venoarterial-ECMO, despite longer support durations and higher rates of severe preoperative right-ventricular dysfunction.
Answers are grounded in this paper and cite their sources.
Venopulmonary-ECMO may reduce complications versus venoarterial-ECMO in right ventricular dysfunction; leaves open optimal bridging strategy pending prospective validation.
BACKGROUND Venopulmonary extracorporeal membrane oxygenation (ECMO) has emerged as a promising strategy to support patients in advanced respiratory failure as a bridge to lung transplantation. This study compared mid-term outcomes of lung transplantation in patients bridged with percutaneous venopulmonary-ECMO, venoarterial-ECMO, or venovenous-ECMO. METHODS We retrospectively analyzed patients who underwent venopulmonary-, venoarterial-, or venovenous-ECMO with the intention to bridge to lung transplantation (2017–2024). Outcomes were analyzed by ECMO configuration at transplantation. In-hospital outcomes, survival, and freedom from chronic lung allograft dysfunction (CLAD) were compared. RESULTS ECMO was implemented in 99 patients (22 venopulmonary-ECMO, 18 venoarterial-ECMO, and 59 venovenous-ECMO) with the intention to bridge. Lung transplantation was achieved in 13 venopulmonary-ECMO patients (59.0%), 12 venoarterial-ECMO patients (66.6%), and venovenous-ECMO patients (72.8%)(p=0.47). Severe preoperative right-ventricular dysfunction was more frequent in patients supported with venoarterial-ECMO or venopulmonary-ECMO than with venovenous-ECMO (66.6% and 61.5% vs. 9.3%, p<0.01). ECMO duration was longest in patients with venopulmonary-ECMO (median 42 days) as compared with venovenous-ECMO or venoarterial-ECMO (10 and 13 days, respectively; p<0.01). One-year survival post-transplant was 100%, 73%, and 95%, and 3-year survival was 100%, 55%, and 77%, with venopulmonary-ECMO, venoarterial-ECMO, and venovenous-ECMO, respectively (p=0.04). CLAD-free survival was 87.5% with venopulmonary-ECMO, 50.0% with venoarterial-ECMO, and 69.1% with venovenous-ECMO (p<0.01). CONCLUSIONS Despite longer ECMO duration and severe right-ventricular dysfunction, venopulmonary-ECMO achieved comparable bridging outcomes as venovenous-ECMO and better mid-term survival than venoarterial-ECMO.
No takes yet. Share an insight, caveat, or question.
Fujimoto et al. (2026) conducted a cohort in Advanced respiratory failure bridged to lung transplantation (n=99). Venopulmonary-ECMO vs. Venoarterial-ECMO or Venovenous-ECMO was evaluated on 3-year survival post-transplant (p=0.04). Venopulmonary-ECMO bridging to lung transplant achieved better 3-year survival than venoarterial-ECMO and comparable survival to venovenous-ECMO.
Synapse has enriched 10 related papers. Consider them for comparative context: